Donepezil HCL Tablets 5 mg Recalled for Subpotency
Jubilant Cadista Pharmaceuticals is recalling Donepezil HCL Tablets, USP, 5 mg (Lot # DN120006A, exp. 12/2021) because the tablets are subpotent—meaning they contain less active ingredient than specified. The recall affects 14,544 bottles distributed nationwide.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as Class III, a lower-risk category. No illnesses, injuries, or adverse events are reported in the source text. The defect is subpotency (reduced active ingredient), which is a quality issue rather than a safety hazard like contamination or toxicity.
Plain-English summary
Jubilant Cadista Pharmaceuticals, Inc. is recalling Donepezil HCL Tablets, USP, 5 mg in 90-count bottles (NDC 59746-329-90), manufactured by Jubilant Generics Ltd. in India. The recall applies to Lot # DN120006A with an expiration date of 12/2021.
The reason for recall is that the tablets are subpotent, meaning they contain less of the active ingredient than intended. Donepezil is used to treat symptoms of mild to moderate Alzheimer's disease.
The recalled product was distributed nationwide. A total of 14,544 bottles have been affected. This is a voluntary recall initiated by the firm on August 20, 2021, and the FDA classified it as Class III on August 31, 2021.
Patients taking this medication should contact their healthcare provider or pharmacist about their treatment and whether they have received tablets from the affected lot. The recall was terminated on April 5, 2022.
The recalled product
- Product
- Donepezil HCL Tablets, USP, 5 mg, 90-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd. India, Marketed by: Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801 NDC 59746-329-90
- Manufacturer
- Jubilant Cadista Pharmaceuticals, Inc.
- Category
- Drug — Prescription / Tablet
- Hazard
- subpotency
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # DN120006A
- exp. date 12/2021
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27